Literature DB >> 10769629

17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells.

J Zheng1, S K Kulp, Y Zhang, Y Sugimoto, M A Dayton, M V Govindan, R W Brueggemeier, Y C Lin.   

Abstract

BACKGROUND: Protein tyrosine phosphatase gamma (PTP gamma) has been implicated as a potential tumor suppressor gene in kidney and lung adenocarcinomas. We have previously shown that PTP gamma mRNA expression levels are lower in DES-induced kidney tumors than in normal kidneys of Syrian hamsters. The goals of the present study were to determine if PTP gamma mRNA is present in both normal and cancerous human breast cells, and to investigate the estrogenic regulation of PTP gamma mRNA expression in these cell types.
METHODS: Primary cultured human breast cells derived from surgical specimens of mammoplasty and breast cancer patients, as well as human breast cancer cell lines were used for the study. RT-PCR and RNase protection assay was utilized to detect and quantify levels of PTP gamma mRNA among the cell types used and between control and 17 beta-estradiol (E2)-treated cells. Transient transfection of human estrogen receptor (ER) into MDA-MB-231 human breast cancer cells was performed to establish the role of ER in the regulation of PTP gamma mRNA expression.
RESULTS: The results show that PTP gamma mRNA is expressed in primary cultured human breast cells isolated from mammoplasty and breast cancer patients, as well as in human cancer cell lines, and that E2 significantly inhibits PTP gamma expression in ER-positive human breast cancer cells via an ER-mediated mechanism. We show that PTP gamma mRNA levels are lower in human breast cancer cells than in normal human breast cells. Furthermore, we report that PTP gamma mRNA expression is inhibited by E2 in a dose-dependent manner in primary cultured breast cells. After treatment with 20 nM E2 for 24 hours, PTP gamma mRNA was significantly suppressed in primary cultured cancerous and non-cancerous cells from breast cancer patients, as well as in the ER-positive MCF-7 cell line by 50%, 85%, and 66%, respectively. In contrast, the PTP gamma mRNA expression levels did not change in similarly treated ER-negative MDA-MB-231 cells. Sensitivity to E2-induced suppression could be restored (94% inhibition) by transfecting MDA-MB-231 cells with an ER expression plasmid.
CONCLUSIONS: Our results are the first to suggest that PTP gamma is a potential estrogen-regulated tumor suppressor gene in human breast cancer which may play an important role in neoplastic processes of human breast epithelium.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10769629

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

Review 1.  Receptor protein tyrosine phosphatase from stem cells to mature glial cells of the central nervous system.

Authors:  Smaragda Lamprianou; Sheila Harroch
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'.

Authors:  Guang Lin; Victoria Aranda; Senthil K Muthuswamy; Nicholas K Tonks
Journal:  Genes Dev       Date:  2011-07-01       Impact factor: 11.361

3.  Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.

Authors:  Bhuvaneswari Ramaswamy; Sarmila Majumder; Satavisha Roy; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Mamoun Younes; Charles L Shapiro; Tasneem Motiwala; Samson T Jacob
Journal:  Mol Endocrinol       Date:  2008-12-18

4.  Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.

Authors:  Ping-Hui Sun; Lin Ye; Malcolm D Mason; Wen G Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-04       Impact factor: 4.553

5.  PTPN14 is required for the density-dependent control of YAP1.

Authors:  Wenqi Wang; Jun Huang; Xin Wang; Jingsong Yuan; Xu Li; Lin Feng; Jae-Il Park; Junjie Chen
Journal:  Genes Dev       Date:  2012-09-01       Impact factor: 11.361

6.  Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer.

Authors:  Françoise Révillion; Carole Puech; Fanja Rabenoelina; Dany Chalbos; Jean-Philippe Peyrat; Gilles Freiss
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

7.  Characterization of PTPRG in knockdown and phosphatase-inactive mutant mice and substrate trapping analysis of PTPRG in mammalian cells.

Authors:  Wandong Zhang; Katerina V Savelieva; David T Tran; Vladimir M Pogorelov; Emily B Cullinan; Kevin B Baker; Kenneth A Platt; Sean Hu; Indrani Rajan; Nianhua Xu; Thomas H Lanthorn
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

8.  Protein tyrosine phosphatase µ (PTP µ or PTPRM), a negative regulator of proliferation and invasion of breast cancer cells, is associated with disease prognosis.

Authors:  Ping-Hui Sun; Lin Ye; Malcolm D Mason; Wen G Jiang
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

9.  Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications.

Authors:  Weihong Zhao; Jiancheng Luo; Shunchang Jiao
Journal:  Sci Rep       Date:  2014-10-13       Impact factor: 4.379

10.  Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.

Authors:  Shao-ying Li; Rong Li; Yu-li Chen; Li-kuang Xiong; Hui-lin Wang; Lei Rong; Rong-cheng Luo
Journal:  BMC Genet       Date:  2014-06-11       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.